KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Current Liabilities (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Total Current Liabilities for 13 consecutive years, with $41.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 17.43% to $41.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $41.8 million, a 17.43% increase, with the full-year FY2025 number at $41.8 million, up 17.43% from a year prior.
  • Total Current Liabilities was $41.8 million for Q4 2025 at Xenon Pharmaceuticals, up from $38.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $41.8 million in Q4 2025 to a low of $8.0 million in Q1 2022.
  • A 5-year average of $24.0 million and a median of $23.7 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: crashed 76.32% in 2021, then soared 181.77% in 2023.
  • Xenon Pharmaceuticals' Total Current Liabilities stood at $14.3 million in 2021, then soared by 58.51% to $22.7 million in 2022, then grew by 20.13% to $27.3 million in 2023, then skyrocketed by 30.5% to $35.6 million in 2024, then rose by 17.43% to $41.8 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Total Current Liabilities are $41.8 million (Q4 2025), $38.3 million (Q3 2025), and $33.0 million (Q2 2025).